AllakosALLK
About: Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
Employees: 131
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
5,000% more call options, than puts
Call options by funds: $51K | Put options by funds: $1K
1% less funds holding
Funds holding: 101 [Q1] → 100 (-1) [Q2]
4% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 24
5.17% less ownership
Funds ownership: 93.83% [Q1] → 88.66% (-5.17%) [Q2]
24% less capital invested
Capital invested by funds: $104M [Q1] → $78.5M (-$25.4M) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
53% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 38
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
JMP Securities Jonathan Wolleben 49% 1-year accuracy 31 / 63 met price target | 362%upside $3 | Market Outperform Reiterated | 26 Sept 2024 |
Jefferies Kevin Strang 0% 1-year accuracy 0 / 1 met price target | 54%upside $1 | Hold Maintained | 18 Jul 2024 |